Abstract: A splice holder is disclosed comprising elongate opposed members each comprising a plurality of splice receivers each comprising an inner surface defining a plurality of apertures for deceiving a plurality if different diameters of optic fiber splices.

Abstract: A splice holder is disclosed comprising elongate opposed members each comprising a plurality of splice receivers each comprising an inner surface defining a plurality of apertures for deceiving a plurality if different diameters of optic fibre splices.

Abstract: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.

Abstract: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.

Abstract: A system may comprise at least one device information file that contains emulation information about at least one device and an emulator that is adapted to read the at least one device information file and provide an on-screen display (“OSD”) emulation of the at least one device. A method may comprise the acts of identifying a device information file that comprises emulation information about a set-up procedure associated with at least one device, invoking an emulation of the set-up procedure associated with the device based on the emulation information and providing instruction to a user based on the emulation of the set-up procedure.